Clinical trials: Peritoneal Cancer
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase II trial studies the side effects of PD 0360324 and cyclophosphamide and to see how well they work in treating patients with high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer that has come…
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT02948101
- Testing
- Anti-CSF1 Monoclonal Antibody PD-0360324, Cyclophosphamide, Laboratory Biomarker Analysis
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Stage IV Gastric Cancer With Metastasis
Nonintervention Study on Peritoneal Metastasis of Stage IV Gastric Cancer
This is a non-interventional study，aim to observe the safety and efficiency of different treatment regimen for peritoneal metastasis of Stage IV gastric cancer in the real world
- Trial name
- NCT03237507
- Testing
- S-1, oxaliplatin, Hyperthermic Intraperitoneal
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Harbin Medical University
Fallopian Tube Cancer, Ovarian Cancer
UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00072267
- Testing
- 7-hydroxystaurosporine, topotecan hydrochloride
- Where
- 4 sites in Canada
- Sponsor
- University Health Network, Toronto
Peritoneal Carcinomatosis
Intravital Microscopy (IVM) in Patients With Peritoneal Carcinomatosis (PC)
This study will investigate the tumor-associated vasculature of patients with peritoneal carcinomatosis, or cancer that spreads along the inner abdominal lining.
- Trial name
- NCT03517852
- Testing
- Human Intravital Microscopy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Chemotherapy, Gastric Cancer
FLOT Combined With PD-1 in the First-line Treatment of Patients With Advanced Gastric Cancer and Peritoneal Metastasis
In this study, patients with advanced gastric adenocarcinoma whose peritoneal metastasis and peritoneal nodule pathologically confirmed metastasis and/or exfoliative cytology were confirmed as the clinical stage of peritoneal…
- Trial name
- NCT04886193
- Testing
- FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU), Treprizumab, Tiggio capsule (S-1)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
SL03-OHD-105 is an open-label, multicenter, phase 1b trial designed to evaluate SL-172154 administered in combination with pegylated liposomal doxorubicin (PLD) or mirvetuximab soravtansine (MIRV) in patients with platinum…
- Conditions
- Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer
- Trial name
- NCT05483933
- Testing
- Pegylated Liposomal Doxorubicin + SL-172154, Mirvetuximab + SL-172154
- Where
- 21 sites in United States, Canada and 2 more
- Volunteers
- 86 people
- Sponsor
- Shattuck Labs, Inc.
Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IV
Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer
Te hypothesized that two cycles of neoadjuvant chemotherapy followed by interval debulking surgery would improve survival in advanced epithelial ovarian, fallopian, and primary peritoneal cancer because reduction of one cycle of…
- Conditions
- Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IV, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- ROCOCO (NCT03693248)
- Testing
- Two cycles of neoadjuvant chemotherapy
- Where
- South Korea
- Volunteers
- 298 people
- Sponsor
- Seoul National University Hospital
Ovarian Cancer
Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
This is an open-label, single-arm, international, multicenter Multiple Patient Expanded Access Program (MPEAP). The program is designed to provide treatment access to olaparib tablets for patients with platinum-sensitive relapsed…
- Trial name
- NCT03079687
- Testing
- Olaparib tablets
- Where
- 13 sites in United States
- Sponsor
- AstraZeneca
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase I/II trial studies the side effects and best dose of ganetespib when given together with paclitaxel and to see how well they work in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal…
- Conditions
- Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
- Trial name
- NCT01962948
- Testing
- paclitaxel, ganetespib, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Fox Chase Cancer Center
Ovarian Cancer, Fallopian Tube Cancer
Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer
The purpose of this research is to study Vitamin D3 replacement for patients at high risk of developing ovarian, fallopian tube, or peritoneal cancer, and see if the Vitamin D3 replacement may be able to prevent the cancer.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT01744821
- Testing
- Arm A: Vitamin D3 Group
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Northwestern University
Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma
YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy
This research trial studies chitinase 3-like 1 (cartilage glycoprotein-39) (YKL-40) in serum samples from patients with newly diagnosed stage III-IV ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer…
- Conditions
- Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma
- Trial name
- NCT00899093
- Testing
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
- Where
- 131 sites in United States
- Volunteers
- 2,500 people
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer, Fallopian Tube Cancer
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
This is a study that will look at the effects and how useful investigational drug olaparib is as a neoadjuvant treatment (treatment given as to shrink a tumor before the main treatment) prior to surgery in patients with recurrent…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Neoadjuvant Treatment, Debulking Surgical Procedures
- Trial name
- NEO (NCT02489006)
- Testing
- Olaparib, Platinum-based Chemotherapy
- Where
- 9 sites in Canada, New Zealand and 2 more
- Volunteers
- 71 people
- Sponsor
- University Health Network, Toronto
Colorectal Neoplasms
Immunotoxin in Peritoneal Carcinomatosis- ImmunoPeCa Trial
The purpose of this study is through a phase I/II clinical trial to assess the safety and toxicity of intraperitoneally administered MOC31PE immunotoxin, given on the 1.postoperative day after cytoreductive surgery (CRS) and…
- Trial name
- ImmunoPeCa (NCT02219893)
- Testing
- MOC31PE Immunotoxin
- Where
- Norway
- Volunteers
- 15 people
- Sponsor
- Oslo University Hospital
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This randomized phase I/IIb trial studies side effects and best dose of atezolizumab when given together with guadecitabine and CDX-1401 vaccine and to see how well they work in treating patients with ovarian, fallopian tube, or…
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT03206047
- Testing
- Atezolizumab, DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Guadecitabine
- Where
- 17 sites in United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Neoplasms
Prophylactic Surgery Plus HIPEC With CO2 in Patients Affected by Colorectal Carcinoma. CHECK Study.
This is a phase III randomized, multicenter study with two different arm: experimental: prophylactic surgery plus HIPEC CO2 performed with mitomycin comparator: standard surgery Adjuvant treatment after surgery is mandatory…
- Trial name
- CHECK (NCT03914820)
- Testing
- HIPEC CO2 surgery, Standard surgery, Mitomycin
- Where
- 16 sites in Italy
- Volunteers
- 330 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Ovarian Cancer, Fallopian Tube Neoplasms
Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill")
Participants with ovarian cancer usually get the drugs carboplatin and paclitaxel as initial treatment. In many participants the tumor will shrink, or even disappear, after treatment with these drugs.
- Conditions
- Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Neoplasm
- Trial name
- NCT00391118
- Testing
- enzastaurin, carboplatin, paclitaxel
- Where
- 15 sites in Belgium, Germany and 3 more
- Volunteers
- 153 people
- Sponsor
- Eli Lilly and Company
Ovarian Cancer, Fallopian Tube Cancer
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
Optimal Timing of Surgery combined with Maintenance Therapy in the Front-line Treatment of Advanced Ovarian Cancer
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT05200260
- Testing
- Primary debulking surgery, Neoadjuvant chemotherapy, PARP inhibitor
- Where
- 9 sites in China
- Volunteers
- 220 people
- Sponsor
- Shanghai Gynecologic Oncology Group
Gastric Cancer, Peritoneal Metastases
Concomitant Intraperitoneal and Systemic Chemotherapy in Patients With Extensive Peritoneal Carcinomatosis of Gastric Origin
Gastric cancer with peritoneal carcinomatosis has a poor prognosis, with little treatment options available. The current treatment strategy consists of palliative systemic chemotherapy.
- Trial name
- NCT05379790
- Testing
- Irinotecan, CAPOX
- Where
- 2 sites in Netherlands
- Volunteers
- 20 people
- Sponsor
- Erasmus Medical Center
Peritoneal Malignancy, Ovarian Cancer
Perioperative Exercise and Nutritional Optimisation Prehabilitation Before Surgery for Patients With Peritoneal Malignancy
People who are diagnosed with cancer of the colon/rectum/appendix/ovaries that spreads into the lining of the tummy and some ovarian cancers or people with pseudomyxoma peritonei can often undergo intensive treatment including…
- Conditions
- Peritoneal Malignancy, Ovarian Cancer, Rectum Cancer, Appendix Cancer
- Trial name
- PANO (NCT05305820)
- Testing
- Exercise, Nutrition
- Where
- 3 sites in Ireland
- Volunteers
- 36 people
- Sponsor
- Dublin City University
Fallopian Tube Carcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer
This phase II trial studies how well olaparib and cediranib maleate work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back after a period of improvement (recurrent).
- Conditions
- Fallopian Tube Carcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Ovarian Carcinoma
- Trial name
- NCT02345265
- Testing
- Biopsy Procedure, Biospecimen Collection, Cediranib Maleate
- Where
- 20 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)